All News

20 April 2007

MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE(R) MoleculeAntibodies

19 April 2007

Viventia Biotech generates novel human anti-cancer antibody, VB1-050, and identifies its novel targetAntibodies

19 April 2007

Anti-Cancer Agent Avastin(R), Approved in JapanAntibodies

18 April 2007

Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACRAntibodies

18 April 2007

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical StudiesAntibodies

18 April 2007

Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal ModelsAntibodies

17 April 2007

Data Presented at AACR Meeting Shows Peregrine’s Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer ModelsAntibodies

17 April 2007

Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer PatientsAntibodies

17 April 2007

YM BioSciences’ Partner Daiichi Sankyo Receives Clearance for Initial Clinical Trial in JapanAntibodies

13 April 2007

XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 DiabetesAntibodies

13 April 2007

Genmab Initiates HuMax-EGFr Combination Study in Non Small Cell Lung CancerAntibodies

7 April 2007

FDA approves Cangene’s HepaGam B(TM) for a second indication; for use in hepatitis B-positive liver transplant recipientsAntibodies

5 April 2007

Cerimon Pharmaceuticals Initiates ARREST UC-1, a Global Phase 2b Study of Basiliximab in Patients with Steroid-Refractory Ulcerative ColitisAntibodies

5 April 2007

AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO’s Novel Anti-HGF AntibodyAntibodies

5 April 2007

Crucell Announces Start of Rabies Phase I Antibody Cocktail Clinical Study in India four months after launching initial US TrialAntibodies

5 April 2007

Genzyme Files for Expanded Label for Campath(R) as First-Line Treatment for B-CLL PatientsAntibodies

5 April 2007

Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III Head and Neck Cancer StudyAntibodies

5 April 2007

Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III Head and Neck Cancer StudyAntibodies

4 April 2007

Pharmexa and Affitech enter into an exclusive license agreement to promote Diabody technologyAntibodies

4 April 2007

Viventia Biotech initiates patient treatment for Vicinium(TM) Phase II bladder cancer trialAntibodies

4 April 2007

WILEX gives positive update of current pivotal Phase III trial of RENCAREX(R)Antibodies

3 April 2007

Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in PsoriasisAntibodies

31 March 2007

Astellas Licenses Regeneron Velocimmune(R) Technology For Discovering Human Monoclonal AntibodiesAntibodies

30 March 2007

XTL Announces the Completion of Phase I Study with XTL-6865 in Patients with Chronic Hepatitis CAntibodies

30 March 2007

Anthrax Monoclonal Antibody Valortim(TM) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax InfectionAntibodies

30 March 2007

NEOPHARM Reports on FDA MeetingAntibodies

29 March 2007

Avastin Approved in Europe for First Line Treatment of Women with Metastatic Breast CanceAntibodies

29 March 2007

MorphoSys and Astellas Enter Antibody Partnership – Deal Seals MorphoSys’s Third Japanese Pharmaceutical AllianceAntibodies

28 March 2007

Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with GenentechAntibodies

28 March 2007

Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular DegenerationAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

PD-1 Agonists Pipeline Review

Report Package: “Drug the Undruggable” Technologies

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

TL1A Inhibitor Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins